Effectiveness of New Alzheimer’s Disease Treatments Under Scrutiny

A growing body of recent research is casting doubt on the clinical significance of newly approved Alzheimer’s disease treatments, with multiple independent analyses suggesting that their benefits may be minimal for most patients despite regulatory approval and widespread media attention as potential “breakthroughs.”

The scrutiny follows the U.S. Food and Drug Administration’s accelerated approval of amyloid-targeting drugs such as lecanemab and donanemab, which are designed to slow cognitive decline by clearing amyloid-beta plaques from the brain. While these drugs have shown statistically significant reductions in plaque burden in clinical trials, recent reviews question whether the observed changes translate into meaningful improvements in daily functioning or quality of life for patients.

A Cochrane review published in early 2024 and updated in 2025 concluded that the available evidence does not support a clinically important benefit from amyloid-modifying therapies for people with Alzheimer’s disease. The analysis, which pooled data from multiple randomized controlled trials, found that while the drugs produced small statistical changes in cognitive scores, the magnitude of effect fell below thresholds considered meaningful by patients and caregivers.

Limited Real-World Impact Despite Biological Activity

Further analysis by researchers at University College London, published in The Lancet Neurology, estimated that patients taking lecanemab would experience only a delay in symptom progression equivalent to a few months over an 18-month treatment period. The study emphasized that such gains, while detectable in clinical assessments, may not be noticeable in everyday activities like managing finances, remembering appointments, or recognizing family members.

Safety Concerns Complicate Risk-Benefit Calculation

Critics also point to the safety profile of these drugs, which includes risks of brain swelling (amyloid-related imaging abnormalities, or ARIA) and microbleeds. In clinical trials, up to one in five patients experienced some form of ARIA, requiring regular MRI monitoring and, in some cases, discontinuation of treatment. These risks raise questions about whether the marginal cognitive benefits justify the burden of frequent imaging, infusions every two weeks, and potential neurological complications.

Scientific Debate Intensifies Over Amyloid Hypothesis

The controversy has reignited long-standing debate over the amyloid hypothesis—the idea that reducing amyloid plaques will meaningfully alter the course of Alzheimer’s disease. While amyloid accumulation remains a hallmark of the disease, some researchers argue that targeting it alone may be insufficient, especially given that cognitive decline often continues even after substantial plaque reduction.

Other experts maintain that amyloid-lowering therapies may still have value, particularly if administered earlier in the disease process or combined with other approaches targeting tau protein, neuroinflammation, or synaptic health. Ongoing trials are investigating combination therapies and preventive use in asymptomatic individuals at genetic risk.

Regulatory Pathways Under Review

In response to the growing skepticism, some regulatory bodies are re-evaluating the standards used for accelerated approval. The FDA’s use of surrogate endpoints—such as amyloid reduction—as a basis for approval has come under scrutiny, with calls for greater emphasis on patient-centered outcomes like independence in daily living and caregiver burden.

Meanwhile, European regulators have taken a more cautious stance. The European Medicines Agency has not approved lecanemab for use in the European Union, citing insufficient evidence of clinical benefit relative to risks.

What This Means for Patients and Families

For individuals living with Alzheimer’s disease and their families, the current landscape underscores the importance of discussing treatment options thoroughly with neurologists. While amyloid-targeting drugs may offer a small slowing of decline for some, they are not curative, do not restore lost function, and require significant time and medical oversight.

Clinicians recommend focusing on evidence-based supportive care, including cognitive stimulation, physical activity, management of cardiovascular risk factors, and access to community resources and caregiver support programs—all of which have demonstrated benefits in maintaining quality of life.

As research continues, the emphasis remains on identifying interventions that not only alter biological markers but also make a tangible difference in how patients experience their day-to-day lives.